The clinical feasibility, safety, and potential effectiveness of combining PDK1 inhibitors in anti-PD1/PDL1-based drug therapy in BCs deserve further verification, which might lead to breakthroughs in BC treatment. This evidence concerns the gene PDK1 and breast cancer.